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RE: Monitoring and Tracking Genetic Resources 
 
Dear Mr. Hodges, 
 
I am writing to you as an interested party and to lend my support to your efforts in facilitating the negotia-
tions and resolving the text of the International Regime for Access and Benefit Sharing. 
 
I am the lead author on the report entitled Studies on Monitoring and Tracking Genetic Resources using 
Persistent Identifiers that was commissioned by the Secretariat in 2008 (See UNEP/CBD/WG-
ABS/7/INF/2) and a fellow of the American Association for the Advancement of Science and the Society 
for Industrial Microbiology. Since 1996, I have been a professor in the Department of Microbiology and 
Molecular Genetics at Michigan State University. 
 
Some tools have recently been developed using technology described in the above-mentioned report to 
examine US patent grants to commercial and non-commercial research entities. I would like to share 
some of the findings (attached) and describe how this tool works prior to the critical discussions that will 
be held in the upcoming meetings in Montreal and Nagoya. To briefly summarize, there has been a steady 
increase in commercially oriented biological research in US universities during the last 15 years that has 
resulted in a significant number patent grants. A similar trend is emerging for non-US universities and is 
likely to continue. At the same time, US patent grants to commercial research entities in the same areas of 
research declined slightly. Taking into account the circumstances of the recently resumed session for 
WG-ABS9 in July in Montreal, it would seem to be in the interests of the international negotiating group, 
as well as the Co-chairs for the meeting, there be some appropriate mechanism to monitor all research 
activities. 
 
The methods used in the analysis are derived from a proof-of-concept for such a mechanism that is al-
ready in place for use in the field of microbiological research. I am at your disposal and will be happy to 
discuss this matter with you at your convenience. 
 
 
Yours sincerely, 
 
 
 
George M. Garrity, Sc.D. 
Professor, Microbiology & Molecular Genetics 
Tele 517.214.8821 
email garrity@msu.edu 
http://www.mmg.msu.edu	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INTRODUCTION 
The life sciences have changed radically since the Convention on Biological Diversity first opened for 
signatures in 1992. Traditional organism-based approaches to discovery and use of genetic resources have 
been supplanted by molecular approaches. Biodiversity prospecting is more likely to be a programmatic 
bioinformatics activity rather than an activity conducted by field scientists. Access to genetic resources is 
no longer centered on a hunt for novel species. Rather, the hunt is for novel genes and metabolic path-
ways that can be cloned into well-understood expression systems and readily scaled-up for industrial pro-
duction. Information about contemporary research, development, and manufacturing practices needs to be 
addressed, especially when those genes do not need to be associated with their native host at the time of 
discovery. Information about the research organizations participating in all phases of the discovery and 
development process also needs to be considered, especially when it involves partnerships between aca-
demic and industrial organizations.  
 
We present a high-level view of recent trends in the issuance of US patent grants to commercial and non-
commercial research organizations, and introduce a technology that is already in place which can be ap-
plied to monitoring the use of genetic materials by various stakeholders in an open and transparent man-
ner, as intended under the International Regime for Access and Benefit Sharing (ABS). 
 
TECHNICAL BACKGROUND AND INFORMATION SOURCES 
We recently used tools that were built on the technology described in the white paper, Studies on Moni-
toring and Tracking Genetic Resources using Persistent Identifiers that was commissioned by the Secre-
tariat in 2008 (UNEP/CBD/WG-ABS/7/INF/2) to examine US patent grants to US and non-US based 
commercial and non-commercial research organizations in which at least one named species of Bacteria 
or Archaea was mentioned. The rationale for conducting this study was to establish if there is a factual 
basis for the assumption that non-commercial research organizations do not proactively pursue patent pro-
tection for their inventions in which genetic resources are involved.  
 
Our study made use of a database and technology belonging to NamesforLife, LLC (East Lansing, MI, 
USA; http://services.namesforlife.com) that was developed to support a name resolution service for use in 
the life sciences. The methodology employs a novel data model and persistent identifiers to monitor and 
track name changes that result in cases where the same organism is known by multiple names over time. 
The current target group is bacteria and archaea, but the methodology is generalizable. The persistent 
identifiers are used to directly access various classes of information that relate to each validly named or-
ganism. Application software developed by the company scans electronic versions of published articles, 
documents or database records to detect biological names and either embeds the correct persistent identi-
fier for future use or provides end-users with direct access to information about the named organism di-
rectly from the page that is displayed in a web browser (Figure 1). Current applications provide access to 
concise information, including history of the name, synonyms, repositories where the organism is avail-
able, key literature references and links to specific gene and genome sequences, where available. The data 
model is extensible and supports the inclusion of virtually any type of information that might be tied to a 
specific organism, and can easily include links to digital copies of PICs, MTAs, or similar documents, for 
users with the appropriate privileges. 
 
The company also maintains information about the occurrence of all bacterial and archaeal names in each 
document processed by our tools. This “nomenclatural fingerprint” can be used to index and retrieve the 
documents relating to a specific organism or group of organisms, even if name changes may have oc-
curred over time. The technology also allows proactive monitoring of the scientific, technical, medical, 
regulatory and patent literature and harvesting of new information on any validly named organism.  
 
 
Figure 1. An example of an annotated US patent application from the NamesforLife patent database. Note linked names 
present in the body of the document and the N4LGuide pop-up showing detailed information for the species Caldicel-
lusurptor saccharolyticus. A complete listing of all bacterial and archaeal names found in this patent application, along 
with frequency distribution of names is shown in the right sidebar. Source, NamesforLife, LLC. 
 
NOTABLE FINDINGS 
From January 19711 through July 2010, there were 92,063 patent grants making reference to one or more 
bacteria or archaea. As expected, US and non-US companies were awarded most of these patents (51.2 
and 32.2%, respectively). What was unexpected was the finding that US academic institutions (including 
museums and herbaria) ranked third, with 9.2% of the patent grants. The number of patent grants to non-
US academic institutions was relatively small in comparison (1.2%). What is noteworthy is the overall 
upward trend in patent grants issued to both US and non-US academic institutions. These have increased 
by four-fold since the first Conference of the Parties. During the same time, patent grants to non-US 
commercial entities dropped by 20% and those to US-based companies remained essentially unchanged.   
 
In addition to the changes in technology mentioned above, academic institutions have also changed, espe-
cially in the US. Since 1980, recipients of federal funding are required to commercialize discoveries of 
faculty, staff and students, whenever possible. What is less obvious is that the inventions belong to the 
institutions, not the faculty or staff, as do all of the research funds, materials, research records and equip-
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  The data from the USPTO available in digital form between 1971 and 1975 is incomplete. Also, our preliminary analy-
sis of the data is based on the first assignee mentioned in each patent grant. We have not yet quantified the instances of 
multiple assignees. This should not affect the basic trend, but may underestimate the number of patent grants to non-
commercial entities.	  
ment. Faculty members are also encouraged to interact with commercial entities to help increase revenues 
and fund their research. Faculty members also have the right to pursue research on any university-owned 
invention created by other faculty members, with or without the consent of the inventors. As a result, no 
faculty member can guarantee that their work will not be commercialized, thus the argument that there is 
a distinction between commercial and non-commercial research is difficult to defend, at least within the 
US. It is our understanding that similar policies are being pursued by institutions in the EU. Although the 
impact that these changes will have on Access and Benefit Sharing can only be quantified retrospectively 
and anecdotally, it is likely to be greater than anticipated by those who advocate special treatment for 
non-commercial research. 
 
 
Figure 2. Cumulative number of US patent grants referencing bacteria and/or archaea to different categories of in-
ventors Source, NamesforLife, LLC. 
 
What is not discernable from our current analysis is the number of licensing arrangements that have oc-
curred between academic institutions and commercial entities. Similarly, our analysis does not reveal the 
number of company sponsored research activities at academic institutions that may result in patentable 
discoveries that are assigned to the sponsor. These are generally private transactions and not recorded, 
especially when the private academic institutions are involved. We think that the above evidence is con-
vincing and that the distinction between commercial and non-commercial research has become increas-
ingly blurred. Both providers and commercial users of genetic resources have reason to be concerned if 
non-commercial research would be exempt from the ABS regime or treated differently. 
 
CONCLUSION 
Establishment of the International Regime for ABS will require delicately balancing the needs of both 
providers and users. This will necessitate an element of trust, but what is lacking in the current environ-
ment is a level of trust that would ordinarily exist between parties entering into a commercial agreement. 
In the absence of such a trusted relationship, what is required are independent methods of verification that 
parties to an agreement are abiding by the stated terms. Even the best intentioned research can have unex-
pected or unintended outcomes. If appropriate mechanisms can be put in place to monitor all research 
activity, it will uncover those events that should trigger sharing of knowledge and/or revenue, as intended 
by the Convention on Biological Diversity, even when those events are far removed into the future. It is 
entirely feasible to do this in a publicly transparent way. The key pieces are already in place.  
